Clinical trial NCT00087555 - References

Fibromyalgia — Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Citation(s)

•   A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy
  Sleep. 2003 Feb 1;26(1):31-5.
•   A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy
  Sleep. 2002 Feb 1;25(1):42-9.
•   Russell IJ, Perkins AT, Michalek JE; Oxybate SXB-26 Fibromyalgia Syndrome Study Group
  Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2009 Jan;60(1):299-309. doi: 10.1002/art.24142.
•   Scharf MB, Baumann M, Berkowitz DV
  The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003 May;30(5):1070-4.
•   The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms
  J Toxicol Clin Toxicol. 2003;41(2):131-5.
•   U
  S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004 Mar;5(2):119-23.

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Comparing the Effects of Orally Administered Xyrem(R) (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia

Details for clinical trial NCT00087555